The “Smart Chemo” Stocks Revolutionizing Cancer Treatment

Dear Reader,

Today I want to talk to you about a very touchy and very personal subject: cancer and chemotherapy.

We all know how brutal cancer is, and how brutal chemotherapy is.

I remember growing up my grandmother was the first person I knew who had cancer.

I was very young at the time, but she seemed fine until she started the chemo, and then she was very sick.

I remember back then there used to be an expression…

“The chemo will get you before the cancer ever does.”

That always struck me.

I remember reading a study published in 2014 in The Lancet Oncology, that chemotherapy kills up to 50% of cancer patients at some hospitals.

Now, some of this is due to the type of care received. But that number, 50%, just shocked me.

I dug deep into the research at the time, when I was battling my own health issues.

What I learned is that chemotherapy really didn’t just attack cancer cells. It also attacked healthy cells.

And in that way, the analogy I used is that chemo treatments were like the “dumb bombs” dropped in WWII.

Just imagine flying over Germany and dropping bombs everywhere just to hit one factory – indiscriminate.

But thankfully, new drugs are emerging we’ve been talking about called “antibody drug conjugates,” or ADCs.

ADCs are part of a new class of drugs dubbed “smart chemo,” because they’re more like precision-guided missiles.

They go right after cancer cells.

And we’ve done very well the past couple of years focusing on “smart chemo” stocks.

===

NVIDIA buys 7 million shares of AI-biotech.

There’s an AI biotech selling for under $10 a share that seems poised to soar in 2024…

ARK Investment recently bought 6.8 million shares…

Bayer just signed a deal worth as much as $1.5 billion to have them develop new drugs…

And NVIDIA has just partnered with them.

Get the name of the stock here.

===

You think about ImmunoGen we recommended and it got taken over for 463% above our recommended price…

Seagen, we recommended which was taken over by Pfizer for a nice, fast profit in Takeover Targets.

We’ve done well and I wanted to bring your attention back to a special report we wrote a few months back: “Smart Chemo.”

Inside, we highlight the different companies we like that are leading this ADC/”Smart Chemo” revolution.

One of the companies in that special report is Daiichi Sankyo (SYM: DSKYF).

I’m putting its name out there as a public service announcement.

They have a new drug called Enhertu which is a breakthrough breast cancer drug.

To me, Daiichi is the best big pharma company you’ve never heard of – it’s like Japan’s “Pfizer.”

We recommended shares back in February at $32, it went to $45 and now it’s at $39 a share so it’s pulled back a bit.

In our “Smart Chemo” special report, we focus on a few of these stocks. This is just one of them.

The reason I like Daiichi is its Enhertu is the most potent drug ever developed for breast cancer.

I’m revealing the name to you, even though we’re in the business of selling stock research, because we’re talking about breast cancer.

I’ve had a lot of friends who have gone through this.

This is the most serious stuff in the world.

And I want to make sure, God forbid, if you or your loved one ever have to deal with this that you go to your doctor and you ask about Enhertu.

If that drug applies to your condition then God-willing you get access to it because it has stopped tumors in their tracks. It’s pretty powerful.

But this is part of this new class of ADCs – “Smart Chemo” drugs – and the companies that are making these new drugs are really changing how we treat cancer.

I’m very bullish on this in the long-term.

Oncology is something I’m very interested in…

It’s something we’ve done very well on at Biotech Insider.

We’ve killed it the past six years investing in oncology stocks.

So I just wanted to say that I’m a big believer in “Smart Chemo.”

They’re doing to cancer drugs what smart bombs, precision-guided weapons, did to warfare…

Just revolutionizing the way we fight cancer.

I hope you never need it as a patient, but you certainly might want it as an investor.

Here’s my full report on “Smart Chemo.”

Have a wonderful day.

“The Buck Stops Here”

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.